No Data
No Data
Botuo Biotech (688767.SH): Currently, POCT industry competition is fierce, and POCT products are under pressure to reduce prices
Gelonghui, May 13 | Botuo Biotech (688767.SH) recently said during a survey reception from institutional investors that currently the POCT industry is fiercely competitive, and POCT products are under certain price reduction pressure.
Botuo Biotech (688767.SH): Will continue to focus on POCT testing tracks
Gelonghui, May 13 | Botuo Biotech (688767.SH) recently said during a survey receiving institutional investors that the company will continue to focus on the POCT testing circuit, give full play to the technology, product, quality and sales advantages that the company has accumulated over the years, and launch new products with higher cost performance, higher sensitivity, and closer to customer usage needs in colloidal gold technology. In terms of new technology platforms, efforts are being made to expand the variety of immunofluorescence products, increase the number of registration certificates for immunofluorescence products, further improve product quality through microfluidic control technology, and create new technology products with differentiated advantages. At the same time, the company is working hard to find the right shape on the outside
Botuo Biotech (688767.SH): COVID-19 related assets have been prepared for depreciation in 2023
Gelonghui, May 13 | Botuo Biotech (688767.SH) recently said during a survey reception from institutional investors that the total asset impairment losses calculated by the company in 2023 were 588.364 million yuan, mainly inventory impairment losses, with a small portion being credit impairment losses. COVID-19 related assets have been prepared for depreciation in 2023 and will not have an impact on subsequent reporting periods.
Botuo Biotech (688767.SH): Domestic sales of influenza A and B testing products achieved rapid growth in 2023. Non-COVID-19 infectious disease series products increased 84.98% year-on-year
Gelonghui, May 13丨Botuo Biotech (688767.SH) recently said during a survey receiving institutional investors that the operating revenue of drug testing and infectious disease testing series products in 2023 accounts for more than 80% of the company's total revenue. Domestic sales of influenza A and B testing products achieved rapid growth in 2023. Non-COVID-19 infectious disease series products increased by 84.98% over the same period last year. The drug abuse (drug) testing series products also achieved a certain increase over the same period last year.
Retail Investors Are Hangzhou Biotest Biotech Co.,Ltd.'s (SHSE:688767) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥404m Last Week
Key Insights The considerable ownership by retail investors in Hangzhou Biotest BiotechLtd indicates that they collectively have a greater say in management and business strategy 55% of the business
Botuo Biotech (688767.SH): Purchased 1.9780% of the company's shares at a total cost of 569.302 million yuan
Gelonghui, April 30, 丨 Botuo Biotech (688767.SH) announced that as of April 30, 2024, the company had repurchased 2.109,800 shares of the company's shares through centralized bidding transactions, accounting for 1.9780% of the company's total share capital of 106,666,667 shares. The highest price of the repurchase transaction was 33.48 yuan/share, the lowest price was 22.23 yuan/share, and the total amount of capital paid was RMB 569.302 million (excluding transaction fees such as stamp duty and transaction fees).
No Data